telaglenastat   Click here for help

GtoPdb Ligand ID: 9053

Synonyms: CB-839 | CB839
PDB Ligand
Compound class: Synthetic organic
Comment: Telaglenastat (CB-839) is an investigational noncompetitive (allosteric) glutaminase inhibitor [1]. It is one of the structures claimed in patent US8604016 [2], where it is compound 670. The anti-cancer activity of CB-839 was first reported in preclinical studies in triple-negative breast cancer (TNBC) cells in vitro and in vivo [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 15
Topological polar surface area 160.12
Molecular weight 571.16
XLogP 4.25
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(Nc1ccc(nn1)CCCCc1nnc(s1)NC(=O)Cc1ccccn1)Cc1cccc(c1)OC(F)(F)F
Isomeric SMILES O=C(Nc1ccc(nn1)CCCCc1nnc(s1)NC(=O)Cc1ccccn1)Cc1cccc(c1)OC(F)(F)F
InChI InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
InChI Key PRAAPINBUWJLGA-UHFFFAOYSA-N
References
1. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J et al.. (2014)
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Mol Cancer Ther, 13 (4): 890-901. [PMID:24523301]
2. Li J, Chen L, Goyal B, Laidig G, Stanton TF, Sjogren EB. (2013)
Heterocyclic inhibitors of glutaminase.
Patent number: US 8604016 B2. Assignee: Calithera Biosciences Inc.. Priority date: 21/11/2011. Publication date: 10/12/2013.